Swedish biopharma Wilson Therapeutics AB has been talking to regulatory bodies and is now drafting plans to advance its lead asset WTX101 into Phase III next year after a Phase II trial met its primary endpoint treating patients with the condition known as Wilson's Disease.
An inherited disorder characterized by too much copper in the liver, brain and other tissues, Wilson's Disease can prove fatal...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
